Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-07-29Clinical Trial Update: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension [Phase 2, Phase 3]
A Phase 2/3 clinical trial update for QLS-111-FDC in open-angle glaucoma and ocular hypertension has been completed.
-
CLINICAL_TRIALS trial_result · 2026-07-15Clinical Trial Update: Long-term Safety and Efficacy Extension Trial of Bimatoprost SR [Phase 3]
Phase 3 long-term safety and efficacy extension study of Bimatoprost SR has completed.
-
CLINICAL_TRIALS trial_result · 2026-07-06Clinical Trial Update: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension [Phase 2, Phase 3]
A Phase 2/Phase 3 clinical trial update for QLS-111-FDC in open-angle glaucoma and ocular hypertension; status is active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction [Phase 3]
Phase 3 trial update reporting completion of evaluation for reformulated PG324 ophthalmic solution aimed at reducing intraocular pressure. T…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: DSLT for Reducing Medication in Glaucoma
Clinical trial update indicates a study evaluating DSLT to reduce glaucoma medications is currently recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-09FDA Approved: COSOPT PF — Supplemental Application (Thea Pharma Inc.)
The FDA approved a supplemental application for COSOPT PF (dorzolamide hydrochloride and timolol maleate) by Thea Pharma Inc., marking an ad…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension [Phase 2, Phase 3]
Status update for a Phase 2/3 trial of QLS-111-FDC in open-angle glaucoma and ocular hypertension; recruitment is currently ongoing.
-
CLINICAL_TRIALS trial_result · 2026-04-01Clinical Trial Update: 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
A completed clinical trial evaluating 24-hour wear performance and safety of the miLens contact lens intended for intraocular pressure monit…
-
CLINICAL_TRIALS research · 2026-03-31Clinical Trial Update: Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension [Phase 2]
A Phase 2 clinical trial comparing BL1107 eye drops to timolol for primary open-angle glaucoma or ocular hypertension, currently recruiting.
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Effect of Infusion Warming on Mannitol Infusion Pain in Patients With Acute Ocular Hypertension [NA]
This completed clinical trial evaluated whether warming a mannitol infusion reduces infusion-related pain in patients with acute ocular hype…
-
EMA approval · 2026-03-24EMA Authorised: Roclanda (Latanoprost;netarsudil mesilate) — Santen Oy
The European Medicines Agency has authorised Roclanda, a fixed-dose combination of latanoprost and netarsudil mesilate, for use in open-angl…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients [Phase 4]
This entry describes a Phase 4 trial comparing Rocklatan to latanoprost in open-angle glaucoma and ocular hypertension, which is currently r…
-
CLINICAL_TRIALS research · 2026-03-23Clinical Trial Update: AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension [Phase 1, Phase 2]
This ClinicalTrials.gov entry describes a Phase 1/2 study of AGN-193408 SR for open-angle glaucoma and ocular hypertension, currently recrui…
-
FDA approval · 2026-03-18FDA Approved: APRACLONIDINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for apraclonidine from Sandoz Inc.
-
FDA approval · 2026-03-18FDA Approved: IOPIDINE 1% — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) from Harrow Eye, LLC, indicating a…
-
FDA approval · 2026-03-17FDA Approved: COMBIGAN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for COMBIGAN (brimonidine tartrate and timolol maleate) submitted by Allergan, Inc.
-
FDA approval · 2026-03-11FDA Approved: BRIMONIDINE TARTRATE — Original Application (Gland Pharma Limited)
FDA approved the original application for brimonidine tartrate ophthalmic solution from Gland Pharma Limited. The approval adds a generic op…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use [Phase 4]
A Phase 4 clinical trial from the University of Miami is evaluating biomarkers of ocular surface damage related to topical ocular hypotensiv…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: Efficacy of the Nanodropper Device on Intraocular Pressure in Patients With Glaucoma [NA]
A terminated clinical trial evaluating the Nanodropper Device for reducing intraocular pressure in glaucoma and ocular hypertension has post…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance [Phase 4]
Phase 4 clinical trial evaluating aqueous humor dynamics to understand intraocular pressure variance in glaucoma and ocular hypertension.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg
This clinical trial update describes an observational study evaluating the updated inserter for the travoprost intracameral implant (75 mcg)…
-
FDA approval · 2026-02-25FDA Approved: TAFLUPROST OPHTHALMIC — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for tafluprost ophthalmic from Prasco Laboratories, enabling the marketing of a generic tafluprost o…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy [NA]
A clinical trial evaluating a Carbopol 980 NF 0.2% based medical device for managing Dry Eye Syndrome in patients with Glaucoma or Ocular Hy…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: Direct vs Standard SLT for Glaucoma: A Noninferiority Trial [Phase 4]
This Phase 4 clinical trial compares Direct SLT to Standard SLT for open-angle glaucoma and ocular hypertension in a noninferiority design; …
-
EMA approval · 2026-02-09EMA Authorised: Azopt (brinzolamide) — Novartis Europharm Limited
EMA authorised Azopt, brinzolamide 1% suspension, for open-angle glaucoma and ocular hypertension in the European Union. Novartis Europharm …